Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model

Phytotherapy Research

Volumn 23, Issue 1, 2009, Pages 132-135

  Baluchnejadmojarad, Tourandokht ^a   Roghani, Mehrdad ^b   Nadoushan, Mohammad Reza Jalali ^b   Bagheri, Maryam ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

6 hydroxydopamine; Genistein; Parkinson's disease; Rat; Rotation

Indexed keywords

APOMORPHINE; GENISTEIN; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; HISTOLOGY; MALE; NERVE CELL; NEUROPROTECTION; NISSL STAINING; NONHUMAN; PARKINSONISM; RAT; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; GENISTEIN; MALE; MOTOR ACTIVITY; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PHYTOESTROGENS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

PARKINSONIA; RATTUS;

EID: 58149520608     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2564     Document Type: Article

References (21)

1. Azcoitia I, Moreno A, Carrero P, Palacios S, Garcia-Segura LM. 2006. Neuroprotective effects of soy phytoestrogens in the rat brain. Gynecol Endocrinol 22: 63-69.
2. Blum-Degen D, Haas M, Pohli S et al. 1998. Scavestrogens protect IMR 32 cells from oxidative stress-induced cell death. Toxicol Appl Pharmacol 152: 49-55.
3. Burke RE, Macaya A, Devivo D, Kenyon N, Janec EM. 1992. Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons. Neuroscience 50: 559-569.
4. Cyr M, Calon F, Morissette M, Di Paolo T. 2002. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 27: 12-27.
5. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
6. De Girolamo LA, Hargreaves AJ, Billett EE. 2001. Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. J Neurochem 76: 650-660.
7. Du B, Ohmichi M, Takahashi K et al. 2004. Both estrogen and raloxifene protect against beta-amyloid-induced neuro-toxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade. J Endocrinol 183: 605-615.
8. Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T. 1996. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Mol Brain Res 39: 127-136.
9. Gelinas S, Martinoli MG. 2002. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J Neurosci Res 70: 90-96.
10. Goodman Y, Bruce AJ, Cheng B, Mattson MP. 1996. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippo-campal neurons. J Neurochem 66: 1836-1844.
11. Grandbois M, Morissette M, Callier S, Di Paolo T. 2000. Ovarian steroids and raloxifene prevent MPTP induced dopamine depletion in mice. Neuroreport 11: 343-346.
12. Green PS, Gridley KE, Simpkins JW. 1996. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 218: 165-168.
13. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. 1998. Gender differences in Parkinson's disease. Clin Neurophar-macol 21: 118-121.
14. Muthane U, Ramsay KA, Jiang H et al. 1994. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/b1 and CD-1 mice. Exp Neurol 126: 195-204.
15. Paxinos G, Watson C. 1986. The Rat Brain in Stereotaxic Co-ordinates, 2nd edn. Academic Press: San Diego.
16. Sauer H, Oertel WH. 1994. Progressive degeneration of nigro-striatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuro-science 59: 401-415.
17. Schwarting RK, Huston JP. 1997. Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicology 18: 689-708.
18. Schwarting RKW, Huston JP. 1996. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. Prog Neurobiol 50: 275-331.
19. Shapiro RM, Glick SD, Camarota NA. 1987. A two-population model of rat rotational behavior: effects of unilateral nigro-striatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res 426: 323-331.
20. Singh M, Dykens JA, Simpkins JW. 2006. Novel mechanisms for estrogen-induced neuroprotection. Exp Biol Med 231: 514-521.
21. Wu SS, Frucht SJ. 2005. Treatment of Parkinson's disease: what's on the horizon? CNS Drugs 19: 723-743.